Which has better valuation and earnings, AKTS or UPB?

Aktis Oncology has higher revenue and earnings than Upstream Bio. Aktis Oncology is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 184.07 -$63.73M -$0.38 N/A Upstream Bio $3.32M 108.86 -$143.44M -$2.91 N/A

Does the media favor AKTS or UPB?

In the previous week, Aktis Oncology had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Aktis Oncology's score of 0.41 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, UPB or ARDX?

Ardelyx has higher revenue and earnings than Upstream Bio. Ardelyx is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $3.32M 108.86 -$143.44M -$2.91 N/A Ardelyx $407.32M 2.94 -$61.60M -$0.23 N/A

Is UPB or ARDX more profitable?

Ardelyx has a net margin of -13.58% compared to Upstream Bio's net margin of -4,718.96%. Ardelyx's return on equity of -38.11% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets Upstream Bio -4,718.96% -43.82% -42.27% Ardelyx -13.58% -38.11% -11.85%

Does the media favor UPB or ARDX?

In the previous week, Ardelyx had 4 more articles in the media than Upstream Bio. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Ardelyx's score of 0.74 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORIC or UPB?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Upstream Bio. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Oric Pharmaceuticals' score of 0.44 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVLN or UPB?

In the previous week, Upstream Bio had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Upstream Bio and 2 mentions for Avalyn Pharma. Upstream Bio's average media sentiment score of 0.90 beat Avalyn Pharma's score of 0.05 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INBX or UPB?

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Inhibrx Biosciences and 3 mentions for Upstream Bio. Inhibrx Biosciences' average media sentiment score of 0.91 beat Upstream Bio's score of 0.90 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Upstream Bio (UPB) Competitors

$6.64 +0.23 (+3.50%)

As of 10:30 AM Eastern

Compare

UPB vs. AKTS, ARDX, ORIC, AVLN, and INBX

Should you buy Upstream Bio stock or one of its competitors? MarketBeat compares Upstream Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upstream Bio include Aktis Oncology (AKTS), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), Avalyn Pharma (AVLN), and Inhibrx Biosciences (INBX).

How does Upstream Bio compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Aktis Oncology currently has a consensus target price of $34.60, suggesting a potential upside of 54.43%. Upstream Bio has a consensus target price of $33.17, suggesting a potential upside of 399.12%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Aktis Oncology has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Aktis Oncology's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Upstream Bio	-4,718.96%	-43.82%	-42.27%

28.8% of Aktis Oncology shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aktis Oncology has higher revenue and earnings than Upstream Bio. Aktis Oncology is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	184.07	-$63.73M	-$0.38	N/A
Upstream Bio	$3.32M	108.86	-$143.44M	-$2.91	N/A

In the previous week, Aktis Oncology had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Aktis Oncology's score of 0.41 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aktis Oncology beats Upstream Bio on 12 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Ardelyx?

Upstream Bio (NASDAQ:UPB) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Ardelyx had 4 more articles in the media than Upstream Bio. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Ardelyx's score of 0.74 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Upstream Bio currently has a consensus target price of $33.17, indicating a potential upside of 399.12%. Ardelyx has a consensus target price of $15.73, indicating a potential upside of 224.61%. Given Upstream Bio's higher probable upside, research analysts plainly believe Upstream Bio is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

58.9% of Ardelyx shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ardelyx has higher revenue and earnings than Upstream Bio. Ardelyx is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$3.32M	108.86	-$143.44M	-$2.91	N/A
Ardelyx	$407.32M	2.94	-$61.60M	-$0.23	N/A

Upstream Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Ardelyx has a net margin of -13.58% compared to Upstream Bio's net margin of -4,718.96%. Ardelyx's return on equity of -38.11% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Ardelyx	-13.58%	-38.11%	-11.85%

Summary

Ardelyx beats Upstream Bio on 11 of the 17 factors compared between the two stocks.

How does Upstream Bio compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oric Pharmaceuticals currently has a consensus price target of $19.27, indicating a potential upside of 62.98%. Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 399.12%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Oric Pharmaceuticals has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Oric Pharmaceuticals' return on equity of -35.33% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Oric Pharmaceuticals has higher earnings, but lower revenue than Upstream Bio. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Upstream Bio	$3.32M	108.86	-$143.44M	-$2.91	N/A

Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Upstream Bio. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.90 beat Oric Pharmaceuticals' score of 0.44 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oric Pharmaceuticals beats Upstream Bio on 9 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Avalyn Pharma has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Avalyn Pharma's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Avalyn Pharma has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Upstream Bio	$3.32M	108.86	-$143.44M	-$2.91	N/A

In the previous week, Upstream Bio had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Upstream Bio and 2 mentions for Avalyn Pharma. Upstream Bio's average media sentiment score of 0.90 beat Avalyn Pharma's score of 0.05 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma currently has a consensus price target of $59.00, suggesting a potential upside of 100.75%. Upstream Bio has a consensus price target of $33.17, suggesting a potential upside of 399.12%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Avalyn Pharma and Upstream Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Upstream Bio compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Inhibrx Biosciences has higher earnings, but lower revenue than Upstream Bio. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	940.10	-$140.05M	-$8.39	N/A
Upstream Bio	$3.32M	108.86	-$143.44M	-$2.91	N/A

Inhibrx Biosciences has a beta of 3.51, suggesting that its stock price is 251% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Inhibrx Biosciences currently has a consensus target price of $150.00, indicating a potential upside of 80.05%. Upstream Bio has a consensus target price of $33.17, indicating a potential upside of 399.12%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Inhibrx Biosciences and 3 mentions for Upstream Bio. Inhibrx Biosciences' average media sentiment score of 0.91 beat Upstream Bio's score of 0.90 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Inhibrx Biosciences beats Upstream Bio on 9 of the 17 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$361.78M	$3.53B	$6.79B	$12.85B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-2.28	7.36	280.19	25.31
Price / Sales	108.86	1,266.96	645.11	114.43
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.06	16.90	11.01	6.29
Net Income	-$143.44M	-$12.52M	$3.48B	$347.49M
7 Day Performance	3.83%	1.39%	1.81%	2.25%
1 Month Performance	-11.52%	-6.48%	-3.36%	-2.82%
1 Year Performance	-57.43%	48.83%	62.28%	19.84%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	2.7767 of 5 stars	$6.65 +3.5%	$33.17 +399.1%	-58.7%	$361.78M	$3.32M	N/A	38	Positive News Upcoming Earnings
AKTS Aktis Oncology	2.2215 of 5 stars	$22.97 -5.1%	$34.60 +50.6%	N/A	$1.29B	$6.50M	N/A	76	Upcoming Earnings
ARDX Ardelyx	2.5953 of 5 stars	$5.09 +0.6%	$15.73 +209.0%	+15.0%	$1.25B	$407.32M	N/A	90	Upcoming Earnings
ORIC Oric Pharmaceuticals	2.3277 of 5 stars	$11.91 -0.9%	$19.27 +61.8%	+4.7%	$1.24B	N/A	N/A	80	News Coverage Earnings Report Upcoming Earnings
AVLN Avalyn Pharma	2.8665 of 5 stars	$27.79 +0.6%	$59.00 +112.3%	N/A	$1.23B	N/A	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. AKTS, ARDX, ORIC, AVLN, and INBX

How does Upstream Bio compare to Aktis Oncology?

Summary

How does Upstream Bio compare to Ardelyx?

Summary

How does Upstream Bio compare to Oric Pharmaceuticals?

Summary

How does Upstream Bio compare to Avalyn Pharma?

Summary

How does Upstream Bio compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. AKTS, ARDX, ORIC, AVLN, and INBX

How does Upstream Bio compare to Aktis Oncology?

Do analysts prefer AKTS or UPB?

Is AKTS or UPB more profitable?

Do insiders & institutionals hold more shares of AKTS or UPB?

Which has better valuation and earnings, AKTS or UPB?

Does the media favor AKTS or UPB?

Summary

How does Upstream Bio compare to Ardelyx?

Does the media favor UPB or ARDX?

Do analysts recommend UPB or ARDX?

Do insiders and institutionals have more ownership in UPB or ARDX?

Which has better earnings & valuation, UPB or ARDX?

Which has more volatility and risk, UPB or ARDX?

Is UPB or ARDX more profitable?

Summary

How does Upstream Bio compare to Oric Pharmaceuticals?

Do institutionals & insiders have more ownership in ORIC or UPB?

Do analysts prefer ORIC or UPB?

Is ORIC or UPB more profitable?

Which has better valuation and earnings, ORIC or UPB?

Which has more risk & volatility, ORIC or UPB?

Does the media favor ORIC or UPB?

Summary

How does Upstream Bio compare to Avalyn Pharma?

Is AVLN or UPB more profitable?

Which has higher valuation and earnings, AVLN or UPB?

Does the media refer more to AVLN or UPB?

Do analysts prefer AVLN or UPB?

Summary

How does Upstream Bio compare to Inhibrx Biosciences?

Which has higher earnings and valuation, INBX or UPB?

Which has more risk & volatility, INBX or UPB?

Is INBX or UPB more profitable?

Do analysts prefer INBX or UPB?

Does the media favor INBX or UPB?

Do insiders & institutionals believe in INBX or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools